NEW YORK, Jan. 25, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTC:PXRB) in the United States District Court for the District of New Jersey on behalf of purchasers of PixarBio (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for PixarBio investors under the federal securities laws.
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for the Company’s securities exhibited manipulative or deceptive activities; (2) the Company’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts lacked veracity; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Washington Post Publisher Will Lewis Steps Down After Layoffs
Anta Sports Expands Global Footprint With Strategic Puma Stake
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



